CHRNA7 and depressive symptom measurement: Pharmacological α7nAChR activation has also demonstrated therapeutic potential in models of other CNS disorders including AD,94 PD,95 schizophrenia,96 ischemic stroke,97 intracerebral haemorrhage,98 LPS-induced anxiety and depression,99 traumatic brain injury (TBI),100 and cardiopulmonary bypass-induced brain injury.101